Business Wire

HAI-ROBOTICS

27.12.2021 10:09:04 CET | Business Wire | Press release

Share
HAI ROBOTICS Celebrates 5th Anniversary, Gets AI Unicorn Nomination by Hurun Report

HAI ROBOTICS , a global leader in Autonomous Case-handling Robotics (ACR) systems for warehouse order fulfillment, is celebrating its fifth anniversary at its new headquarters as it ranks among global unicorns according to this year’s unicorn ranking list from the Hurun Research Institute.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211226005013/en/

The company, a logistics warehousing automation solution provider that secured three rounds of funding in 2021, was nominated along with 300 other Chinese start-ups which were valued at more than US$1 billion as of November this year in a global list totaling 1,058. The list was released last week.

HAI ROBOTICS was founded in late 2016 by a group of like-minded robot enthusiasts who aspire to create value for every warehouse and factory with the vision to push forward human civilization through robotics technology. The company’s birth originated from a revolutionary idea that took shape as early as 2015 – the totes-to-person solution – to improve warehouse operational efficiency, instead of creating a homogenous brand of the then prevalent shelves-to-person material handling.

The solution underwent repeated tests and trials in a real warehouse environment for nearly two years before it was formally introduced into the market. The company’s first project was successfully deployed in Best Logistics’ warehouse in August 2018. Soon the story went viral with great exemplary effect that the ACR solution swiftly secured footholds in factories and warehouses.

“It’s an extraordinary journey for us to grow from the cradle of a small workshop into a company of more than 1,200 employees with five branch offices across the globe today,” said Richie Chen, the company’s founder and CEO. “We’re celebrating our fifth anniversary with gratitude to our customers and investors for their trust and confidence in our team. We’ll keep making innovative products and stay committed to bringing value to our partners.”

Automating a warehouse can be a huge project worthy of careful consideration for any business operator. The concerns could range from the length of necessary deployment time, agility of refitting, affordability to ROIs. The HAI ROBOTICS team kept their users’ concerns in mind when building their products. Hence, they kept refining their ideas and fine-tuning the HAIPICK robots for wider applications and stricter storage requirements.

First and foremost, the HAIPICK ACR solution allows greater space utilization and higher goods-handling precision and efficiency than traditional Goods-to-Person solutions, such as Kiva robots that move an entire rack. With the HAIPICK ACR solution, a warehouse’s storage density can be boosted by 80% to 400% and a worker’s picking speed can be improved 3 to 4 times. In addition, the HAIPICK robots, using QR codes on the floor for navigation, can be deployed within one month with no altering of the interior structure of a warehouse.

Thanks to its easy deployment and flexibility, the solution has been adopted by a wide array of customers who prefer smaller picking units than an entire rack or pallet when automating their warehouses. So far, HAI ROBOTICS has been running more than 300 projects globally in various fields, including e-commerce, 3PL, apparel, electronics, energy, manufacturing, medicine, and more. To provide localized service overseas, it has partnered with dozens of global logistics and supply chain leaders, including LG CNS, MHS, MUJIN, BPS, Savoye, Invar, SSI Schaefer and more.

About HAI ROBOTICS

HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse.

The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.

Founded in 2016 with headquarters in Shenzhen, China, HAI ROBOTICS has set up five subsidiaries in Hong Kong SAR, Japan, Singapore, the U.S. and the Netherlands, serving customers from more than 30 countries and regions. It now has over 1,200 staff, more than 50% of whom are engineers. The company has acquired more than 600 global patents for core intellectual properties involving positioning, robot control and warehouse management. In the latest C and D rounds of funding in 2021, the company raised over US$200 million in total.

Link:

ClickThru

Social Media:

https://www.facebook.com/HAIROBOTICS/videos/?ref=page_internal

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye